Endothelium specific expression regulated by epcr control elements
CA 2270160 A1 · Owner: Esmon, Charles T. · Inventors: Esmon, Charles T.; Gu, Jian-Ming
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The promoter of the EPCR gene has been isolated from both murine (SEQ. ID No. 1) and human (SEQ. ID No. 2) genomic libraries. The promoter has been demonstrated to include a region which results in selective expression in endothelial cells, between -1 and -220 based on the positions relative to the ATG encoding the first amino acid of the murine EPCR protein (nucleotides 3130 to 3350 of SEQ. ID No. 1), and a region which selectively results in expresion in large vessel endothelial cells, as opposed to all endothelial cells located between -700 and -1080 (nucleotides 2270 to 2840 of SEQ. ID No. 1). A thrombin responsive element has been identified in the EPCR promoter from -, 337 to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 7, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 7, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 7, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.